Repligen to repurchase up to 1.25M shares
Biopharmaceutical company Repligen Corp. (Nasdaq:RGEN) said this morning that it will repurchase of up to 1.25 million shares of its common stock, stating that the program “reflects the confidence it has in its business.”
Shares were halted in pre-market trading. For detailed price information and recent news stories about Repligen, click RGEN.
About the Author
Reporter Jennifer Schonberger is based in SmallCapInvestor.com's Washington, D.C. bureau.
Read More
(click a star)
Enter comment: